VioQuest Pharma Subsidiary Signs License Agreement with Merck to Supply Chiral Catalysts and Ligands


MONMOUTH JUNCTION, N.J., Sept. 15, 2005 (PRIMEZONE) -- VioQuest's subsidiary Chiral Quest, Inc., (OTCBB:VQPH) signed a licensing agreement granting Merck & Co., Inc. use of its catalysts for the process development and manufacture of single-enantiomer intermediates and active pharmaceutical ingredients. This agreement provides Merck with access to a broad range of proprietary ligands and catalysts.

About VioQuest Pharmaceuticals, Inc.

VioQuest Pharmaceuticals, Inc. strategy is to acquire and develop late preclinical and early clinical-stage therapies for oncological, viral and autoimmune diseases. The Company recently entered into a definitive merger agreement to acquire Greenwich Therapeutics, which owns exclusive license rights to two anti-cancer agents -- sodium stibogluconate (SSG) and triciribine (TCN-P). VioQuest's life science subsidiary, Chiral Quest, Inc., a pioneer in asymmetric synthesis, offers proprietary chiral catalysts and synthesis expertise for creating important chiral intermediates and products, which improve the safety and efficacy of pharmaceutical products. Through Chiral Quest, VioQuest provides products and services to twelve of the top eighteen pharmaceutical companies at all stages of product life cycles to pharmaceutical and fine chemical manufacturers worldwide. For more information please visit www.vioquestpharm.com.

Forward-Looking Statements: This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that any of VioQuest's research programs and compounds will be successfully commercialized. Risks, uncertainties and assumptions also include the possibility that the market for the sale of certain products may not develop as expected; and that development of these products may not proceed as planned. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2004. VioQuest assumes no obligation and does not intend to update these forward-looking statements.



            

Coordonnées